The Generalist Discount vs. The Clinical Moat
In the broader IT services market, valuation multiples have normalized. As of late 2025, generalist digital transformation firms—even those with strong Salesforce or cloud capabilities—typically trade between 8x and 10x EBITDA. The market views these assets as interchangeable capacity; they are essentially staffing augmentations with a logo. However, a distinct bifurcation has emerged for partners specializing in the Life Sciences vertical, specifically those within the Veeva Systems ecosystem.
Data from 2025 M&A transactions indicates that specialized Life Sciences IT partners, particularly those with deep expertise in Veeva Development Cloud (Vault), are commanding multiples in the 12x to 15x EBITDA range. This "Vertical Premium" is not driven by technology skills alone but by what acquirers call the "Regulatory Moat." A generalist developer can configure a workflow; only a specialist understands why a failed validation in a clinical trial submission can cost a pharma client $10 million in delayed revenue.
For Private Equity sponsors, the arbitrage opportunity is clear. A generalist Salesforce practice trading at 9x can potentially expand its multiple to 12x+ by acquiring and integrating a smaller, high-margin Life Sciences boutique. However, this premium requires a pivot away from the "Commercial Cloud" (CRM) commoditization and toward the high-stakes world of R&D and Clinical Operations.
The 'Vault CRM' Migration Event: A $2B Services Opportunity
The valuation premium for Veeva partners is currently being accelerated by a specific market event: the Great Migration from Salesforce-based Veeva CRM to the proprietary Vault CRM. With Veeva's formal separation from Salesforce scheduled to conclude by 2030, the entire industry—representing approximately 80% of global pharma commercial teams—must migrate their core operating systems. This creates a guaranteed, recession-resistant backlog of high-complexity work for the next four years.
However, not all Veeva revenue is valued equally. M&A due diligence has begun to heavily discount "Commercial Cloud" revenue (sales force automation) that relies solely on seat-count expansion, viewing it as low-moat. In contrast, Veeva R&D Solutions revenue (Clinical, Quality, Regulatory) is growing at double-digit rates and is viewed as "sticky IP." This segment now represents over 50% of Veeva's total revenue, signaling a market shift.
Partners who can bridge the gap—handling the technical migration to Vault CRM while simultaneously optimizing Clinical and Quality workflows—are seeing the highest valuations. Acquirers like Accenture and specialized PE platforms are paying premiums for firms that possess "Clinical DNA": consultants who are essentially scientists and regulatory experts first, and technologists second.
Positioning for the Exit: The 'Paper Tiger' Trap
For founders and PE operating partners looking to exit a Veeva practice in 2026, the primary risk is the "Paper Tiger" designation. In due diligence, buyers are increasingly scrubbing employee certifications against actual billable project history. A firm claiming "Vault Clinical" expertise based on 50 certifications but only three active projects will see its valuation re-traded down to generalist levels.
To capture the 14x premium, firms must demonstrate:
- Revenue Mix: At least 40% of revenue derived from R&D/Vault projects (Clinical, Quality, Regulatory), rather than just Commercial CRM.
- Intellectual Property: Documented accelerators for "validation"—the heavy documentation burden required by the FDA. Accelerators that reduce validation time by 30% are effectively productized revenue.
- Talent Density: A ratio of "Subject Matter Experts" (former industry practitioners) to "Configurators" that exceeds 1:4.
The window to claim this premium is open, driven by the scarcity of talent capable of managing the Vault CRM migration. But as the large SIs (Accenture, Cognizant, Deloitte) continue their consolidation spree, the "mid-market" of available targets is shrinking, potentially driving multiples even higher for the few remaining high-quality assets.
